肺癌恶性胸水患者重组人血管内皮抑素联合顺铂方案胸腔化疗后胸水肿瘤标志物变化与疗效的相关性

摘要

Objective Observe lung cancer patients with malignant pleural effusion in rh-endostation cisplatin chemotherapy scheme after malignant pleural effusion tumor markers of change. Methods Analysis accept rh-endostation cisplatin chemotherapy patients with lung cancer of the malignant pleural effusion 36 cases, observed before and after treatment of tumor marker CEA, TPS and CYFRA21-1 changes, and according to the results of the imaging before and after treatment to change to are compared. Results After chemotherapy, tumor markers like CEA, TPS and CYFRA21-1were decreased, in which CEA, TPS and CYFRA21-1 diminished 44.3% (P<0.05), 53.32% (P<0.05), and32.15% (P<0.05).CEA, TPS, CYFRA 21-1 the curative effect and the clinical curative effect were positively correlated. The three joint test was positively associated with the clinical effect. Conclusion Chest water CEA, CA125 and CYFRA21-1 represent reliable markers for chemotherapy efficacy on patients with lung cancer. Monitoring changes of serum levels of tumor markers would benefit for assessment of chemotherapy efficacy.%目的：观察肺癌恶性胸水患者在重组人血管内皮抑素联合顺铂方案胸腔化疗后胸水肿瘤标志物的变化。方法分析接受管内皮抑素联合顺铂胸腔化疗的肺癌患者36例,观察治疗前后肿瘤标志物CEA、TPS及CYFRA21-1的变化,并根据治疗前后影像学结果的改变来进行对比。结果治疗后CEA、TPS及CYFRA21-1均值与化疗前都有不同程度下降,其中CEA下降44.3%(P＜0.05)，TPS下降53.32%(P＜0.05),CYFRA21-1下降32.15%(P＜0.05)。患者肿瘤标志物疗效与临床疗效的相关性分析结果表明, CEA、TPS、CYFRA21-1的疗效与临床疗效呈正相关。三者联合检测与临床疗效呈正相关。结论肺癌恶性胸水患者肿瘤标志物CEA、CA125、CYFRA21-1水平的改变是反映血管内皮抑素疗效的可靠指标,通过监测患者胸水肿瘤标志物水平的改变可以协助判断治疗疗后疗效。